Clinical trials: RhA - Rheumatoid Arthritis
Moderate to Severe Active Rheumatoid Arthritis
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis
This is a multi-center, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of intravenous HS628 in combination with MTX versus Actemra in combination with MTX, in participants with moderate to…
- Trial name
- NCT06048224
- Testing
- HS628+MTX, Actemra +MTX
- Where
- China
- Volunteers
- 669 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Rheumatoid Arthritis
Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis
BCD-089 is the original therapeutic monoclonal antibody binding the alpha subunit of the IL-6 receptor. The aim of the study is to demonstrate the efficacy and safety of BCD-089 in combination with methotrexate in patients with…
- Trial name
- SOLAR (NCT04227366)
- Testing
- BCD-089, Methotrexat
- Where
- Russia
- Volunteers
- 154 people
- Sponsor
- Biocad
Rheumatoid Arthritis
A Study of Efficacy of Rituximab [Mabthera/Rituxan] in Patients With Rheumatoid Arthritis Using Magnetic Resonance Imaging of the Hand (RESONAR)
This randomized, double-blind, placebo controlled, parallel group study will assess the efficacy and safety of rituximab [MabThera/Rituxan] in patients with severe active rheumatoid arthritis refractory to at least one anti-TNF…
- Trial name
- NCT01117129
- Testing
- rituximab [MabThera/Rituxan], methotrexate
- Where
- Spain
- Volunteers
- 2 people
- Sponsor
- Hoffmann-La Roche
Active Rheumatoid Arthritis
A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
This is a Phase 2 randomized, double-blind, placebo-controlled study with a total duration of 32 weeks from Screening to End-of-Study (EOS) Visit. Approximately 180 participants are planned to be enrolled.
- Trial name
- NCT07409103
- Testing
- ELV001 25 mg, ELV001 75 mg, ELV001 125 mg
- Where
- 34 sites in United States, Serbia and 1 more
- Volunteers
- 180 people
- Sponsor
- Elevara Medicines Limited
Rheumatoid Arthritis, Osteoarthritis
A Single Centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Primary Hip Resurfacing Surgery
The purpose of this study is to monitor the performance and determine the metal ion release of the DePuy ASR™ System in the treatment of patients with hip joint disease requiring hip resurfacing surgery.
- Conditions
- Rheumatoid Arthritis, Osteoarthritis, Post-traumatic Arthritis, Collagen Disorders
- Trial name
- NCT00872794
- Testing
- DePuy ASR™ Hip System
- Where
- South Africa
- Volunteers
- 50 people
- Sponsor
- DePuy International
Arthritis, Rheumatoid
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
A 3-year open-label trial for patients who previously participated in Trial Hx-CD20-403 and who fulfill the eligibility criteria for this trial (GEN413) .
- Trial name
- NCT00655824
- Testing
- ofatumumab
- Where
- 10 sites in United States, Denmark and 3 more
- Volunteers
- 124 people
- Sponsor
- GlaxoSmithKline
Venous Thromboses, Venous Thromboembolism
The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study
Blood clots occurring in the legs and in the lungs are relatively common; they occur in around 3 in a 1000 people per year. They can cause disability and are also potentially life threatening.
- Conditions
- Venous Thromboses, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- NCT03835780
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 266,890 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Rheumatoid Arthritis (RA)
A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)
The purpose of this study is to verify the superiority of ASP015K in combination with MTX or with other disease-modifying antirheumatic drugs (DMARDs) over placebo in terms of efficacy in participants with rheumatoid arthritis…
- Trial name
- NCT03660059
- Testing
- Peficitinib, Plaebo, Disease-modifying antirheumatic drugs (DMARDs)
- Where
- 43 sites in China, South Korea and 1 more
- Volunteers
- 385 people
- Sponsor
- Astellas Pharma China, Inc.
Inflammation, Rheumatoid Arthritis
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis
This trial is conducted in Europe. The aim of the trial is to evaluate the change in disease activity following intravenous (i.v.) administration of two doses of NNC0114-0006 compared to placebo in subjects with active rheumatoid…
- Trial name
- NCT01647451
- Testing
- NNC0114-0006
- Where
- 33 sites in Bulgaria, Hungary and 5 more
- Volunteers
- 62 people
- Sponsor
- Novo Nordisk A/S
Active, Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes
It is not fully clear how rheumatoid arthritis originates and develops, but it is understood that multiple genetic and environmental factors interact to trigger its onset.
- Trial name
- NCT00642629
- Testing
- STA 5326 mesylate
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- Synta Pharmaceuticals Corp.
Rheumatoid Arthritis
Study of the Tolerability of Different SAR153191 Drug Products, That Differ With Respect to Manufacturing Processes and Formulation, at Different Concentrations and Doses in Healthy Male Subjects
Primary objective: To determine the tolerability of different SAR153191 drug products that differ with respect to manufacturing processes and formulation, at different concentrations and doses, after administration of single…
- Trial name
- NCT06159452
- Testing
- SAR153191-P3 drug product, SAR153191-P2 drug product, SAR153191-C1F3 drug product
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Sanofi
Rheumatoid Arthritis
Study to Evaluate Safety and Efficacy of CCX 354-C in Subjects With Rheumatoid Arthritis
The purpose of this study is to evaluate the safety and tolerability of multiple oral doses of CCX354-C at a number of dose levels in subjects with stable rheumatoid arthritis (RA).
- Trial name
- CARAT-1 (NCT01027728)
- Testing
- CCX 354-C
- Where
- 5 sites in Belgium, Romania
- Volunteers
- 24 people
- Sponsor
- Amgen
Rheumatoid Arthritis
A Prospective, Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
This prospective, observational study will evaluate the efficacy, safety and tolerability of RoActemra/Actemra (tocilizumab) in patients with moderate to severe active rheumatoid arthritis who have had an inadequate response or…
- Trial name
- NCT01770834
- Where
- 12 sites in Kuwait, Lebanon and 2 more
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Juvenile Chronic Arthritis
Juvenile Rheumatoid Arthritis
The purpose of this study is to determine the safety of anakinra in patients with Polyarticular-Course Juvenile Rheumatoid Arthritis, a form of rheumatoid arthritis affecting children.
- Trial name
- NCT00037648
- Testing
- Anakinra
- Volunteers
- 86 people
- Sponsor
- Amgen
Rheumatoid Arthritis
Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis
A phase 2a open-label study to evaluate the long-term safety and efficacy of ABX464 50mg as maintenance therapy in patients with moderate to severe rheumatoid arthritis.
- Trial name
- NCT04049448
- Testing
- ABX464
- Where
- 14 sites in Belgium, France and 2 more
- Volunteers
- 40 people
- Sponsor
- Abivax S.A.
Rheumatoid Arthritis
A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis
This study includes two periods. In Period 1, Participants who meet eligibility criteria will be randomized in a 1:1:1 ratio to receive a twice-daily oral LNK01001 Dose A or LNK01001 Dose B or a matching placebo for 12 weeks.
- Trial name
- NCT06099535
- Testing
- LNK01001 Dose A, LNK01001 Dose B
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Lynk Pharmaceuticals Co., Ltd
Rheumatoid Arthritis
A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs
This open-label, single-arm study will evaluate the efficacy and safety of tocilizumab in combination with DMARDs in participants with moderate to severe active rheumatoid arthritis who have an inadequate response to DMARDs.
- Trial name
- NCT00996606
- Testing
- DMARDs, Tocilizumab
- Where
- 11 sites in Italy
- Volunteers
- 58 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disorder that can cause substantial pain and joint tenderness, significant joint damage, and serious disability.
- Trial name
- RA-1 (NCT00221000)
- Testing
- Methoxsalen, Extracorporeal Photopheresis
- Where
- 32 sites in United States, Australia and 9 more
- Volunteers
- 86 people
- Sponsor
- Mallinckrodt
Rheumatoid Arthritis
Safety and Efficacy of the Combination of Diacerein 100 mg Daily and MTX Versus MTX Alone in the Treatment of Early Rheumatoid Arthritis (RA)
To evaluate the efficacy of Diacerein 100 mg daily versus placebo in reducing rheumatoid arthritis symptoms, when added to stable oral MTX therapy in patients with active early RA.
- Trial name
- NCT01264211
- Testing
- Diacerein
- Where
- 2 sites in Thailand
- Volunteers
- 40 people
- Sponsor
- TRB Chemedica
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)
This study will evaluate the safety and effectiveness of MabThera (rituximab) in patients with active rheumatoid arthritis who are receiving methotrexate, and who have a previous or current inadequate response to one prior…
- Trial name
- NCT01272908
- Testing
- rituximab
- Where
- 41 sites in Canada, Sweden
- Volunteers
- 120 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.